hVIVO (HVO.L) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

HVO.L · Stock Price

GBP 0.08+0.01 (+17.39%)

Market Cap: $75.0M

Historical price data

Overview

hVIVO is a mission-critical CRO that accelerates and de-risks infectious and respiratory disease drug development through its globally unique human challenge trial platform. The company has established itself as the partner of choice for top biopharma, leveraging over 14 validated challenge models, a large volunteer database, and integrated lab services to generate rapid, high-quality proof-of-concept data. Its strategy focuses on expanding its service portfolio, geographic footprint, and therapeutic expertise to capitalize on the growing demand for efficient early clinical development solutions.

Infectious DiseasesRespiratory DiseasesCardiometabolic DiseasesDermatology

Technology Platform

Proprietary Human Challenge Trial (HCT) platform featuring over 14 validated disease models, specialist quarantine facilities, and an integrated virology/immunology laboratory (hLAB) for rapid, controlled proof-of-concept testing in healthy volunteers.

Pipeline

10

10 drugs in pipeline

Drug	Indication	Stage
CC-42344 + Placebo	Influenza A	Phase 2
PrEP-001 + G-004	Asthma	Phase 2
PrEP-001	Viral Upper Respiratory Tract Infection	Phase 2
MV-012-968	RSV Infection	Phase 2
PrEP-001	Influenza A H3N2	Phase 2

Opportunities

The growing demand for efficient early-phase drug development, especially in infectious diseases, and the expansion of human challenge models into new therapeutic areas like cardiometabolic disorders present significant growth avenues.

Geographic expansion, particularly in the US, and deeper integration of its full-service CRO offerings offer further upside.

Risk Factors

Operational and reputational risk from adverse events in challenge trials, revenue volatility due to dependency on a limited number of large contracts, and regulatory changes impacting the human challenge trial model constitute primary risks.

Competition and successful execution of expansion strategies are additional concerns.

Competitive Landscape

hVIVO holds a dominant, defensible position in the niche human challenge trial market with few direct commercial competitors. It faces broader competition from large, global CROs in early-phase services and specialized labs, but its integrated platform and scale create significant barriers to entry.

More companies in Diagnostics & Precision Medicine →More companies in United Kingdom →